StemCell Therapy

Seoul, Feb 17 (PTI) The gene editing tool CRISPR-Cas9 may be delivered directly into the eye to treat age-related macular degeneration (AMD) efficiently and safely, a new study has claimed.

AMD is a form of blindness, common in Caucasians, which causes distorted vision and blind spots.

Scientists at the Institute for Basic Science (IBS) in Korea used CRISPR-Cas9 in performing gene surgery in the layer of tissue that supports the retina of living mice.

The most common retinopathies causing blindness are retinopathy of prematurity in children, diabetic retinopathy and AMD in older adults.

In these diseases, abnormally high levels of the Vascular Endothelial Growth Factor (VEGF) are secreted. In AMD, VEGF causes the formation of new blood vessels in the eyes but also leads to leakages of blood and fluid into the eye, damaging an area at the center of the retina called macula.

Injections of anti-VEGF drugs are the most common treatment against AMD, but at least seven injections per year are required, because VEGF is continuously overexpressed by the cells of the diseased retinal pigment epithelium.

Instead of such invasive treatments, scientists believe that gene therapy with the third generation gene editing tool CRISPR-Cas9 could improve the situation.

The injections tackle the effects, but not the main cause of the problem. By editing the VEGF gene, we can achieve a longer-term cure, said KIM Jin-Soo, Director of the Center for Genome Engineering at IBS.

CRISPR-Cas9 can precisely cut and correct DNA at the desired site in the genome. The system works by cutting DNA at a target site, in this case, inside the VEGF gene.

Two year ago, IBS scientists proved that a pre-assembled version of CRISPR-Cas9, or Cas9 ribonucleoprotein (RNP), can be delivered to cells and stem cells to modify target genes.

The pre-assembled complex works rapidly and degrades before the body has time to build up an immune response against it.

In this study, the team successfully injected CRISPR-Cas9 into the eyes of a mice model with wet AMD and locally modified the VEGF gene.

Initially they found that the delivery of the pre-assembled CRISPR-Cas9 complex is more efficient than the delivery of the same components in a plasmid form.

Secondly, the complex disappeared after just 72 hours.

Scientists assessed the whole genome of the animals and found the CRISPR-Cas9 complex modified only the VEGF gene and did not affect other genes.

The progression of the eye disease was monitored by looking at choroidal neovascularisation (CNV), the creation of new blood vessels between the retina and the sclera a common problem of wet macular degeneration and researchers found the CNV area reduced by 58 per cent.

Moreover, a likely side effect, namely cone dysfunction, that takes only 3 days to show in these mice, did not occur a week after the treatment.

The study was published in the journal Genome Research.

This is published unedited from the PTI feed.

E Palanisamy takes oath as Tamil Nadu Chief Minister: All that happened through the day

Odisha Panchayat Election Results 2017 LIVE News Updates: BJD leads in 32, BJP in 29 and Congress in 13 of 175 Zilla Parishad seats

Mumbai University's 'first transgender' student's journey from being sexually harassed to an interior designer is inspirational!

Maharashtra Civic polls 2017: Won't back BJP if Shiv Sena withdraws support, says NCP chief Sharad Pawar

Yeh Hai Mohabbatein 16 February 2017 written update, preview: Will Ishita give Gulabo another chance?

Read more here:
Gene editing surgery may prevent blindness: study - India.com

This entry was posted on February 17, 2017 at 5:45 am and is filed under Blindness. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |